F027 Critical Gaps and Controversies in Laser Treatment of Port Wine Birthmarks and other Vascular Anomalies
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will be devoted to procedural interventions for port wine birthmarks and other vascular anomalies, with a focus on laser treatment, and potential for combination with other approaches. We will hear from experts in the field of PWB ranging from topics including optimal timing for treatment, innovative approaches to improve tolerance and outcomes to laser, opportunities for future targeted therapy to inhibit downstream signaling pathways driven by genetics. In the realm of other vascular anomalies, approaches to infantile hemangiomas, venous and lymphatic malformations, AVMs, and glomulovenous malformations will be reviewed, in combination with medical and/or procedural therapies.
LEARNING OBJECTIVES
Review the optimal timing for laser initiation for port wine birthmarks.
Define the genetics of vascular anomalies including port wine birthmarks, and discuss opportunities for adjuvant targeted therapy based on downstream signaling.
Review innovative approaches to laser treatment for other vascular anomalies including segmental infantile hemangiomas, microcystic lymphatic malformations, venous malformations, and glomulovenous malformations.
SCHEDULE
2:00 PM
Early treatment of port wine birthmarks
Roy G. Geronemus, MD, FAAD
2:20 PM
Complex Vascular Anomalies Cases: Faculty Panel - What Would you Do Next?
2:40 PM
What's Next: Future Directions for the Treatment of Port Wine Birthmarks
Kristen Marie Kelly, MD, FAAD
2:40 PM
Laser for ComplicatedSegmental Infantile Hemangiomas: Who, What, Where, and Why
Denise W Metry, MD, FAAD
3:00 PM
Adding to your toolbox: Laser for other vascular anomalies in a multi-modal approach
Lisa Arkin, MD, FAAD
SPEAKERS
Lisa Arkin, MD, FAAD
Roy G. Geronemus, MD, FAAD
Kristen Marie Kelly, MD, FAAD
Denise W Metry, MD, FAAD
SPEAKER DISCLOSURES
Lisa Arkin, MD, FAAD
Amgen – Investigator(Grants/Research Funding); Eli Lilly – Investigator(Grants/Research Funding); Merck – Consultant (1099 relationship)(Fees); Regeneron – Consultant(Honoraria); Sanofi – Speaker/Faculty Education(Honoraria);
Roy G. Geronemus, MD, FAAD
Allergan, Inc – Investigator(Grants/Research Funding); Allergan, Inc. – Advisory Board(Grants/Research Funding); ArchiMedus – Investigator(Grants/Research Funding); Candela Corporation – Advisory Board(Grants/Research Funding), Investigator(Grants/Research Funding); Lutronic – Advisory Board(Grants/Research Funding), Investigator(Grants/Research Funding); New York Stem Cell Foundation – Investigator(Grants/Research Funding); Syneron Candela – Advisory Board(Grants/Research Funding), Investigator(Grants/Research Funding);
Kristen Marie Kelly, MD, FAAD
BioPhotas Inc. – Investigator(Grants/Research Funding); Candela Corporation – Other(Equipment), Other(No Compensation Received); Cutera – Other(Equipment); Lutronic – Investigator(Equipment), Investigator(Grants/Research Funding); Michaelson Diagnostics – Investigator(Equipment); Michelson Diagnostics – Investigator(Grants/Research Funding); NobelPharma – Consultant (1099 relationship)(Honoraria); Orlucent – Investigator(Grants/Research Funding); Primus Pharmaceuticals – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); R2 Dermatology, Inc. – Investigator(Equipment); Reliant Technologies, Inc. – Other(Equipment); Sciton Inc. – Investigator(Equipment); Sciton, Inc. – Consultant(Honoraria); Shanghai Fudan-Zhangjiang Bio Pharmaceutical Co., Ltd. – Consultant(Honoraria), Investigator(Grants/Research Funding); Thermage – Other(Equipment);
Denise W Metry, MD, FAAD
No financial relationships exist with ineligible companies.